Filing Details

Accession Number:
0000950170-24-029536
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-11 20:02:32
Reporting Period:
2024-03-08
Accepted Time:
2024-03-11 20:02:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
873303 Sarepta Therapeutics Inc. SRPT Pharmaceutical Preparations (2834) 930797222
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1492766 Rudolf Lennart Hans Wigzell 215 First Street
Suite 415
Cambridge MA 02142
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-08 15,000 $13.90 37,840 No 4 M Direct
Common Stock Disposition 2024-03-08 3,155 $123.85 34,685 No 4 S Direct
Common Stock Disposition 2024-03-08 11,745 $123.10 22,940 No 4 S Direct
Common Stock Disposition 2024-03-08 100 $122.39 22,840 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-03-08 15,000 $0.00 15,000 $13.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-02-27 2035-02-27 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.6 to $124.6, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $122.65 to $123.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.